Cloudbreak Pharma Management
Management criteria checks 1/4
We currently do not have sufficient information about the CEO.
Key information
Jinsong Ni
Chief executive officer
US$16.5m
Total compensation
| CEO salary percentage | 9.50% |
| CEO tenure | 5.7yrs |
| CEO ownership | 28.0% |
| Management average tenure | 1.9yrs |
| Board average tenure | 4.7yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2025 | US$17m | US$2m | -US$68m |
| Sep 30 2025 | n/a | n/a | -US$55m |
| Jun 30 2025 | n/a | n/a | -US$42m |
| Mar 31 2025 | n/a | n/a | -US$70m |
| Dec 31 2024 | US$7m | US$898k | -US$99m |
| Dec 31 2023 | US$9m | US$2m | -US$129m |
| Dec 31 2022 | US$801k | US$758k | -US$67m |
Compensation vs Market: Jinsong's total compensation ($USD16.54M) is above average for companies of similar size in the Hong Kong market ($USD245.90K).
Compensation vs Earnings: Jinsong's compensation has increased whilst the company is unprofitable.
CEO
Jinsong Ni (57 yo)
Dr. Jinsong Ni, Ph D., is the Founder and Chief Executive Officer and of Cloudbreak Therapeutics LLC and served as its Chief Scientific Officer. Prior to founding Cloudbreak Therapeutics, Dr. Ni was Scient...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | no data | US$16.54m | 28.03% HK$ 312.5m | |
| Co-Founder | no data | US$3.21m | 7.86% HK$ 87.6m | |
| Chief Scientific Officer & Executive Director | no data | US$3.21m | 1.62% HK$ 18.1m | |
| Chief Patent Officer & Chief Compliance Officer | 2.7yrs | no data | no data | |
| Chief Medical Officer | 4.1yrs | no data | no data | |
| Chief Commercial Officer | no data | no data | no data | |
| Chief Business Officer | less than a year | no data | no data | |
| Company Secretary | 1.2yrs | no data | no data |
Experienced Management: 2592's management team is not considered experienced ( 1.9 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 5.7yrs | US$16.54m | 28.03% HK$ 312.5m | |
| Co-Founder | 5yrs | US$3.21m | 7.86% HK$ 87.6m | |
| Chief Scientific Officer & Executive Director | 4.7yrs | US$3.21m | 1.62% HK$ 18.1m | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Non-Executive Director | less than a year | US$7.00k | no data | |
| Independent Non-Executive Director | less than a year | US$2.00k | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Non-Executive Director | 5yrs | US$106.00k | 3.81% HK$ 42.5m | |
| Non-Executive Director | 4.7yrs | no data | no data | |
| Non-Executive Director | 2.1yrs | no data | no data | |
| Independent Non-Executive Director | 1.3yrs | US$20.00k | no data |
Experienced Board: 2592's board of directors are considered experienced (4.7 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/17 01:20 |
| End of Day Share Price | 2026/07/17 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Cloudbreak Pharma Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.